Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bellus Health, Thallion deal

Bellus completed its acquisition of infectious disease company Thallion for a total cash component of C$6.3

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE